2024-03-20 12:30:27 ET
Summary
- Taysha Gene Therapies, Inc. cohort 2 higher dosing TSHA-102 data from adolescent and adult phase 1/2 REVEAL study treating patients with Rett Syndrome is expected in 2nd half of 2024.
- Cohort 1 data of TSHA-102 treating pediatric patients with Rett Syndrome in phase 1/2 REVEAL study expected mid-2024; Cohort 2 higher dose data 2nd half of 2024.
- The global Rett Syndrome market is expected to reach $515.06 million by 2029.
- Company deprioritized its pipeline to establish new loan and security agreements to move its gene therapies to specific entities; This move also allowed it to extend its cash runway into 2026.
Taysha Gene Therapies, Inc. ( TSHA ) reported positive preliminary results from the phase 1/2 adolescent and Adult REVEAL study, which used its gene therapy TSHA-102 for the treatment of patients with Rett Syndrome. The last time I wrote about this biotech was in August of 2023, where it only had released initial data from one patient. This was a Seeking Alpha article entitled " Taysha Gene Therapies: Rett Syndrome Data Makes This A Must Watch. "...
Read the full article on Seeking Alpha
For further details see:
Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts